Navigation Links
MedAvante Closes $20 Million Financing by Goldman Sachs, Trevi Health Ventures
Date:7/1/2008

clinical trials for psychiatric drugs; we will now be able to bring this same new paradigm to bear in other areas of critical medical need, such as the development of new treatments for Alzheimer's disease and the assessment of the risk of suicidality for all classes of drugs."

The former FDA Deputy Commissioner for Medical and Scientific Affairs, Scott Gottlieb, MD, a member of MedAvante's Board of Directors, commented, "The cost of conducting trials to treat neurological and psychiatric disorders has been increasing rapidly in recent years in large part due to the approaches industry has been using to measure patient response. Larger numbers of patients are being enrolled in psychiatric trials simply because outdated approaches to drug development require more patients to be exposed to an experimental drug to see whether it's working." He continued, "MedAvante has pioneered an approach that offers one of the most effective solutions to improving the efficiency and reliability of psychiatric drug development, enabling new treatments to be assessed more efficiently for safety and effectiveness and potentially reach patients sooner and at lower cost."

Andrew Fink, Managing Director of Trevi Health Ventures, noted, "MedAvante's solution solves the critical problem of enhancing precision and reliability in central nervous system trials head-on. This capital infusion will enable the company to meet the rapidly expanding demand for more accurate psychiatric assessment. Importantly, MedAvante has demonstrated the ability to deliver centralized ratings with the operational precision and scalability needed to expand globally."

Walter Greenblatt & Associates served as MedAvante's exclusive financial advisor in the transaction.

About MedAvante

MedAvante has pioneered and commercialized a solution that addresses one of the global pharmaceutical industry's most intractable problems: the high rate of uninformative or failed studies. MedAvante p
'/>"/>

SOURCE MedAvante, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. OncoVista, Inc. Closes on $6.8 Million Financing and Acquires Control of a Public Shell Company
2. Genmab Discloses Target and Development Plans for HuMax-Inflam
3. Oxford Finance Corporation Closes $7 Million Debt Facility with Othera Pharmaceuticals
4. RoundTable Healthcare Partners Closes Sale of MedAssist Holding, Inc. to Firstsource Solutions Limited
5. Gilde Healthcare Partners Closes EUR 150 Million European Healthcare Venture Fund
6. Symmetry Medical Discloses Accounting Issues at Sheffield, UK Operating Unit and Possible Restatement
7. BioVex Closes Second Round of Series E Financing
8. Pharmaxis Closes Share Purchase Plan
9. The closest look ever at native human tissue
10. Helix BioPharma closes $16.9 million private placement of common shares
11. Senesco Technologies Closes on Additional $4.0 Million of Previously Announced Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/18/2014)... 2014 The International Wheat Genome Sequencing Consortium ... draft sequence of the bread wheat genome. The chromosome-based ... evolution of the large, complex genome of the world,s ... blueprint is an invaluable resource to plant science researchers ... their disposal a set of tools enabling them to ...
(Date:7/17/2014)... July 17, 2014  Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: ... the development and commercialization of products for the treatment ... release results for the second quarter of 2014 on ... The Company will host a conference call ... during which Vanda management will discuss the second quarter ...
(Date:7/17/2014)... The Scripps Research Institute (TSRI) and Hong Kong ... collaborators have found that ancient enzymes, known for ... proteins, evolved myriad other functions in humans. The ... evolution as well as a potentially valuable new ... "These new protein variants represent a previously unrecognized ...
(Date:7/17/2014)... 17, 2014  Exelixis, Inc. (Nasdaq: EXEL ... two cancer treatments cabozantinib (Cabo, Cometriq) and cobimetinib (Cobi). ... company has a partnership with Roche to commercialize, market ... in the treatment of melanoma by late 2015, after ... marketed and distributed in the U.S. by EXEL, and ...
Breaking Biology Technology:Genetic Blueprint of Bread Wheat Genome Unveiled 2Genetic Blueprint of Bread Wheat Genome Unveiled 3Vanda Pharmaceuticals to Announce Second Quarter 2014 Financial Results on August 7, 2014 2Scientists find protein-building enzymes have metamorphosed & evolved new functions 2Scientists find protein-building enzymes have metamorphosed & evolved new functions 3Exelixis, Inc., Analyst Report; The Upside Potential is Worth the Risk by BrokerBank Securities, Inc. 2
... to Apply for Incentive Program, RALEIGH, N.C., ... around the Research Triangle Area (RTA) who provide ... the RTA Health Care,Collaborative, a group of forward-thinking ... is implementing an initiative,known as the Bridges to ...
... SAN FRANCISCO, Calif., Aug. 16 Anesiva,Inc. (Nasdaq: ... in the,Zingo(TM) development program before the markets open ... held at 8:30 a.m. Eastern Time,tomorrow to discuss ... the live audio webcast by dialing,800-340-6289 (international dial: ...
... Indevus,Pharmaceuticals, Inc. (Nasdaq: IDEV ) today ... the U.S. Food and Drug Administration (FDA) for,VALSTAR(R). ... is the only product approved by the FDA ... (CIS) of the,urinary bladder. VALSTAR was removed ...
Cached Biology Technology:Research Triangle Area Health Care Collaborative Launches Bridges to Excellence(R) Initiative to Improve Quality and Lower Costs 2Research Triangle Area Health Care Collaborative Launches Bridges to Excellence(R) Initiative to Improve Quality and Lower Costs 3Research Triangle Area Health Care Collaborative Launches Bridges to Excellence(R) Initiative to Improve Quality and Lower Costs 4Anesiva to Host Conference Call and Webcast Tomorrow to Discuss Encouraging Development in Zingo(TM) Program 2Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy 2Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy 3Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy 4
(Date:7/21/2014)... of Middle East Respiratory Syndrome coronavirus (MERS-CoV) in the ... the virus. The work, published this week in ... Society for Microbiology, indicates that further studies are needed ... the air. , MERS, a serious viral respiratory illness ... people as of June 11, according to the World ...
(Date:7/21/2014)... every movement, researchers have shown for the first time ... farms and pipelines. Those man-made structures probably serve as ... study published in the Cell Press journal Current ... shocked when I first saw the stunning grid pattern ... wind farm in the United Kingdom, says Deborah Russell ...
(Date:7/21/2014)... 2014 Dysfunction in dopamine signaling profoundly changes ... the brain,s prefrontal cortex and may be an ... as schizophrenia, according to UC Irvine scientists. , ... cells that receive this neurotransmitter showed for the ... variety of behavioral and physiological functions regulated in ...
Breaking Biology News(10 mins):Middle East Respiratory Syndrome coronavirus detected in the air of a Saudi Arabian camel barn 2Seals forage at offshore wind farms 2UCI researchers find epigenetic tie to neuropsychiatric disorders 2
... Horizon oil spill temporarily worsened existing manmade problems in Louisiana,s ... for optimism, according to a new study. A study ... Academy of Sciences found the 2010 spill killed off ... and this plant die off resulted in a more-than-doubled rate ...
... Older women with insufficient levels of Vitamin D gained more weight ... new study funded by the National Institutes of Health and published ... study of more than 4,600 women ages 65 and older found ... D in their blood gained about two pounds more than those ...
... The international project LEGATO (Land-use intensity ... and Opportunities in irrigated rice based production systems) ... Ecosystem Services and Ecological Engineering" which will be ... 7 July. LEGATO unites 21 research institutions ...
Cached Biology News:BP Deepwater Horizon oil spill exacerbated existing environmental problems in Louisiana marshes 2BP Deepwater Horizon oil spill exacerbated existing environmental problems in Louisiana marshes 3Low vitamin D levels linked to weight gain in some older women 2
... The Jouan MSC series of Class ... working conditions and certification to the ... regulation ensures that the cabinets cannot ... conditions. Natural lighting, low noise and ...
... are designed to create the ideal environment for ... to 99.9C) , Variable speed control (10 ... whether it be for washing or hybridizing ... temperature inside the chamber, ,is situated above a ...
... engineered for efficient drying down of synthetic ... cover and a post-trap with ammonia neutralizing ... of samples in ammonium hydroxide., , ... , Comes standard with ...
... (for aqueous, other low volatility and noxious ... to specific applications of molecular biology and ... heat-labile samples. The RC systems can be ... and a wide selection of rotors (eliminating ...
Biology Products: